Favorable response to PD-1 receptor inhibitor pembrolizumab as a third-line therapy in ROS1-rearranged advanced lung cancer: A case report and review of the literature

Favorable response to PD-1 receptor inhibitor pembrolizumab as a third-line therapy in ROS1-rearranged advanced lung cancer: A case report and review of the literature

ROS chromosomal rearrangements, which compromise around 1-2% of non-small cell carcinomas, have become an established therapeutic target. While targeted therapy for this mutation usually includes tyrosine kinase inhibitors such as crizotinib or alectinib, we present a unique case of a patient with s...

Full description

Bibliographic Details
Main Authors: Akriti Chaudhry, Kyle Schuppe, Skyler Burke, Veronika Lobova, Quincy Seigel, Carsten Kirby, Sara Chitlik, Mirela Andrei, Erin Kaya
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Current Problems in Cancer: Case Reports
Subjects:
Lung adenocarcinoma
ROS1 mutation
Pembrolizumab
Targeted cancer therapy
Case report
Online Access:http://www.sciencedirect.com/science/article/pii/S2666621922000540

Internet

http://www.sciencedirect.com/science/article/pii/S2666621922000540

Similar Items